Status:
UNKNOWN
The Diagnostic Value of Autoimmune Antibody Detection in Newly Onset and Chronic Epilepsy
Lead Sponsor:
Xijing Hospital
Collaborating Sponsors:
General Hospital of Ningxia Medical University
LanZhou University
Conditions:
Epilepsy
Eligibility:
All Genders
16-70 years
Brief Summary
multi-central and prospectively study the diagnostic value of autoimmune antibody detection in new and chronic epilepsy, and provide reference for clinical practice
Detailed Description
multi-centrally recruit patients with newly onset or chronic epilepsy and hoping to find whether there exist an autoimmune cause. whether the patients receive immune therapy or not will depend on the ...
Eligibility Criteria
Inclusion
- Patients diagnosed with epilepsy according to the diagnostic criteria of International League Against Epilepsy (ILAE) 2017
- Age from 16 to 70 years old
- The etiology of patients with epilepsy is unknown
- The patient or guardian signs an informed consent and can cooperate with the inspection and follow-up for six months
Exclusion
- Patients with hereditary, infectious, and metabolic epilepsy
- The investigation and follow-up cannot be completed due to vision, hearing, language expression, disturbance of consciousness, and impaired understanding, and the guardian cannot replace the completed
- Patients with other progressive or systemic diseases
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04516590
Start Date
August 1 2020
End Date
September 1 2021
Last Update
August 18 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.